Malvern, Pa., March 29, 2023 (Globe NEWSWIRE) FABRIC Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company providing innovative soft tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced its OviTex.® Tissue matrix reinforcement in three cases reported at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) conference from March 29 – April 1, 2023, in Montreal, Canada.
These case reports will help inform surgeons about techniques for using OviTexia in robot-assisted hernia repair. OviTex Tissue Matrix has been uniquely positioned as an acceptable hernia tissue replacement option that can be successfully used in robotic and laparoscopic hernia repair.
“We are excited and honored to have demonstrated the use of OviTexia in robotic hernia repair at SAGES,” said Anthony Koblish, CEO of TELA Bio. “The unique design and handling features of OviTex facilitate its use in minimally invasive procedures and allow surgeons to provide patients with a proven support option that reduces dependence on permanent synthetic mesh.”
1. Robotic Bilateral Transverse Abdominal Component Separation and Diaphragmatic Hernia Repair in an Immunosuppressed Heart Transplant Patient (Steven M Elzein, MD; Mu’ath Adlouni, BS; Ahad Azzimuddin, BS, MBA; Rodolfo J Oviedo, MD, FACS, FSMBS. Houston Methodist Hospital)
2. Robotic Transabdominal Preperitoneal (TAPP) for the treatment of Spigelian Hernias (Yoon Kyung Lee, MD; Daniel Tomey, MD; Roberto Secchi, MD; Alessandro Martinino, MD; Rodolfo Oviedo, MD, FACS, FASMBS, FICS. Houston Methodist Hospital; Universidad Anahuac Queretaro;
3. Traumatic Ventral and Diaphragmatic Hernias: A Case Report (Robert D Larsen, MS; John Azar, MS; Joseph Lewis, MD.
The TELA Bio team will be attending SAGES 2023, Booth #301. For the full agenda, see:
About FABRIC Bio, Inc.
WEB Bio, Inc. (NASDAQ: TELA) is a leading medical technology company dedicated to providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. The company is committed to providing surgeons with advanced, cost-effective soft tissue reconstruction solutions that support the patient’s natural healing response while minimizing long-term exposure to permanent synthetic materials. For more, visit www.telabio.com.
OviTex Reinforced Tissue Matrix is intended for use as a surgical mesh to strengthen and/or repair soft tissue where weakness exists. Indications for use include the repair of hernias and/or abdominal defects that require the use of reinforcing or reducing material to achieve the desired surgical outcome. Do not use OviTex in patients known to be sensitive to materials of sheep (sheep) origin. We use prescription only. For additional important safety information, please see the OviTex Tissue Matrix Instructions for Use.
Be careful about the future, look at the announcements
This press release contains forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Words such as “to,” “to,” “will,” “anticipate,” “believe,” “expect,” “anticipate.” hold,” “predict,” “anticipate,” “project,” “intend,” “intend” or the like, or statements that are about current intentions, beliefs, or expectations; forward-looking statements; and reflect current opinions about WEB management These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those forward-looking through such statements, including, among others, the impact on our business from macroeconomic conditions, including the ongoing response to the COVID-19 pandemic, recessionary concerns, credit instability, and inflationary pressures, potentially impacting our ability to market our products, to demand our products due to the delay in the selection process, labor and staffing. the environment in the health industry, disruptions in our supply chain, or existing pressures around our products, or procedures using our products; our ability to achieve or sustain profitability; our ability to obtain market acceptance for our products and to meet accurate supply and customer demand; to our ability to compete successfully; that data from previous studies related to our products and interim data from ongoing studies cannot be replicated in subsequent studies or indicative of future data; that the data from the clinical studies used in our study may not have reported results in other surgical settings; our ability to expand our product offering; the factory needs a weekend; capacity constraints or delays in the production of our products; maintenance coverage and adequate reimbursement procedures for the use of our products; failure or product failure. These and other risks and uncertainties are described more fully in the “Risk Factors” section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form XK and Quarterly Reports on Form XQ. Any forward-looking statements we make in this announcement speak only as of the time of this press release, and TELA undertakes no obligation to update any forward-looking statements whether as a result of new information, future events or otherwise after the date hereof. newspapers, unless required by applicable law.